Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome plus S-1 as postoperative adjuvant therapy for resected pancreatic cancer
ChiCTR2500101759Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome and tegafur in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Disease-free survival rate at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
irinotecan liposometegafur
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500101759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101759.